M (o) TOR of pseudo-hypoxic state in aging: rapamycin to the rescue

OV Leontieva, MV Blagosklonny - Cell cycle, 2014 - Taylor & Francis
OV Leontieva, MV Blagosklonny
Cell cycle, 2014Taylor & Francis
A groundbreaking publication by Sinclair and coworkers has illuminated the pseudo-hypoxic
state in aging and its reversibility. Remarkably, these data also fit the mTOR-centered model
of aging. Here we discuss that the mTOR pathway can cause cellular pseudo-hypoxic state,
manifested by HIF-1 expression and lactate production under normoxia. We found that
rapamycin decreased HIF-1 and lactate levels in proliferating and senescent cells in vitro.
This reduction was independent from mitochondrial respiration: rapamycin decreased …
A groundbreaking publication by Sinclair and coworkers has illuminated the pseudo-hypoxic state in aging and its reversibility. Remarkably, these data also fit the mTOR-centered model of aging. Here we discuss that the mTOR pathway can cause cellular pseudo-hypoxic state, manifested by HIF-1 expression and lactate production under normoxia. We found that rapamycin decreased HIF-1 and lactate levels in proliferating and senescent cells in vitro. This reduction was independent from mitochondrial respiration: rapamycin decreased lactate production in normoxia, hypoxia, and in the presence of the OXPHOS inhibitor oligomycin. We suggest that pseudo-hypoxic state is not necessarily caused by mitochondrial dysfunction, but instead mitochondrial dysfunction may be secondary to mTOR-driven hyperfunctions. Clinical applications of rapamycin for reversing pseudo-hypoxic state and lactate acidosis are discussed.
Taylor & Francis Online